| Code | CSB-RA896903MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to evinacumab-dgnb, specifically targeting angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 is a hepatocyte-derived protein that functions as a key regulator of lipid metabolism by inhibiting lipoprotein lipase and endothelial lipase, enzymes critical for triglyceride and high-density lipoprotein metabolism. By suppressing these lipases, ANGPTL3 elevates plasma levels of triglycerides, low-density lipoprotein cholesterol, and total cholesterol. Loss-of-function mutations in ANGPTL3 are associated with reduced cardiovascular disease risk, making this protein an attractive therapeutic target for dyslipidemia and related metabolic disorders.
Evinacumab-dgnb is a fully humanized IgG4 monoclonal antibody that neutralizes ANGPTL3 function and has been approved for treating homozygous familial hypercholesterolemia. This biosimilar antibody serves as a valuable research tool for investigating ANGPTL3 biology, exploring lipid metabolism pathways, studying atherosclerosis mechanisms, and evaluating potential therapeutic interventions for cardiovascular and metabolic diseases. It enables researchers to examine the physiological and pathological roles of ANGPTL3 in preclinical models and in vitro systems.
There are currently no reviews for this product.